Aurobindo's Indian manufacturing deal comes amid regulatory turbulence with the U.S., where the company recently recalled a batch of antibiotics after a complaint flagged the presence of a hair in a vial of the drug. Meanwhile, the U.S. FDA in January published a warning letter it slapped on Aurobindo's Telangana, Hyderabad, India, facility following an inspection last August.